CETP INHIBITORS: UPCOMING STRATEGIES TO TREAT ATHEROSCLEROSIS

Authors

  • Kishore Gunda *1, Swaroop kumar .S.L.V.V.S.N., K*1, Anbu.J1, Ravichandiran.V1, Pramod reddy .G2

Keywords:

CETP inhibitors, atherosclerosis, obicetrapib, LDL cholesterol, HDL cholesterol, lipoprotein(a), cardiovascular disease.

Abstract

Atherosclerosis is a chronic vascular disease strongly associated with elevated concentrations of atherogenic apolipoprotein B-containing lipoproteins. Cholesteryl ester transfer protein (CETP) plays an important role in lipid metabolism by transferring cholesteryl esters from high-density lipoprotein to low- and very-low-density lipoproteins. Inhibition of CETP has therefore been investigated as a strategy to increase HDL cholesterol and reduce atherogenic lipoproteins. Early CETP inhibitors produced disappointing results because of off-target toxicity, insufficient cardiovascular benefit, or unfavorable pharmacokinetic properties. However, newer compounds have renewed interest in this therapeutic target. Obicetrapib, a next-generation CETP inhibitor, has demonstrated substantial reductions in LDL cholesterol, apolipoprotein B, non-HDL cholesterol, and lipoprotein(a) when added to existing lipid-lowering therapy [1,2]. The aim of this review is to summarize the mechanisms, previous limitations, and future therapeutic potential of CETP inhibition in atherosclerosis. Current evidence suggests that future CETP-directed therapy will focus less on simply raising HDL cholesterol and more on reducing the overall burden of atherogenic lipoproteins.

References

Chang B, Laffin LJ, Sarraju A, et al. Obicetrapib—the rebirth of CETP inhibitors? Current Atherosclerosis Reports. 2024;26:603–608.

Kastelein JJP, Hsieh A, Dicklin MR, Ditmarsch M, Davidson MH. Obicetrapib: Reversing the tide of CETP inhibitor disappointments. Current Atherosclerosis Reports. 2024;26:35–44.

Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. New England Journal of Medicine. 2007;357:2109–2122.

HPS3/TIMI55–REVEAL Collaborative Group. Effects of anacetrapib in patients with atherosclerotic vascular disease. New England Journal of Medicine. 2017;377:1217–1227.

Recent advances in immunotherapy targeting CETP proteins for atherosclerosis prevention. Human Vaccines & Immunotherapeutics. 2025.

Nicholls SJ, Lincoff AM, et al. CETP inhibition and contemporary lipid-lowering strategies in atherosclerotic cardiovascular disease. Current Atherosclerosis Reports. 2024.

Masson W, Barbagelata L, Lobo M, et al. Lipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis. Atherosclerosis. 2025;407(Suppl):119583.

Downloads

Published

2010-03-03